Diatide gets $12 million from existing investors:
This article was originally published in Clinica
Executive Summary
Diatide, a US company engaged in discovery and commercialisation of disease-specific medical imaging agents and therapeutics, has raised $11.8 million from three of its present shareholders in a private placement. Diatide has a strategic partnership with Nycomed, which has already taken up AcuTect thrombus imaging and P829 tumour imaging products. Diatide says there are five other products in stage II and III clinical trials.